Korro Bio Inc KRRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KRRO is a good fit for your portfolio.
News
-
Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
-
Korro to Participate in Upcoming June Investor and Scientific Conferences
-
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
-
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
-
Korro Announces $70 Million Private Placement
Trading Information
- Previous Close Price
- $38.32
- Day Range
- $34.97–40.00
- 52-Week Range
- $9.15–97.91
- Bid/Ask
- $18.00 / $41.36
- Market Cap
- $338.74 Mil
- Volume/Avg
- 80,097 / 69,182
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 101
- Website
- https://www.korrobio.com
Valuation
|
Metric
|
KRRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.94 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KRRO
|
|---|---|
Quick Ratio | 12.56 |
Current Ratio | 13.18 |
Interest Coverage | — |
Quick Ratio
KRRO
Profitability
|
Metric
|
KRRO
|
|---|---|
Return on Assets (Normalized) | −44.71% |
Return on Equity (Normalized) | −127.24% |
Return on Invested Capital (Normalized) | −83.28% |
Return on Assets
KRRO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Cllsgqbsk | Drcg | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lxfhcxymd | Qlxzvp | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wfxnzmk | Sjfzct | $114.0 Bil | |||
| Moderna Inc
MRNA
| Jjkryqnz | Zsxb | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cfhzqshq | Gtzhm | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Vqfkczvc | Mchbx | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Hhghxtnm | Dswq | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yhfnwtln | Kmlddv | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Frzsnywy | Tkcdx | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Trslgmcs | Zgfjmdx | $11.6 Bil |